Worth considering 3 possible points:

* MRD is a relatively small part of the overall sequencing market.

* There are other likely other routes to Q60+ that may work for many applications.

* Roche doesn't currently beat Illumina on simplex accuracy. But that doesn't mean they never will.

It will certainly be hard for Roche to beat Illumina on simplex accuracy, but I wouldn't rule it out. And I'm reasonably confident that single molecule approaches as a general class can/will at some point (possibly depending on the definition of simplex).